about
Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015Genetically determined Amerindian ancestry correlates with increased frequency of risk alleles for systemic lupus erythematosusImpact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations.International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results.Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture.Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/PaediatriReport on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015.Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.[Laboratory abnormalities and autoantibodies].Progressive facial hemiatrophy (Parry-Romberg syndrome) and antibodies to Borrelia.2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology reportFAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary Sjögren’s syndromeA Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus ErythematosusPrevalence of antinuclear antibodies in patients with habitual abortion and in normal and toxemic pregnanciesAntibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosisPrevalence of antinuclear antibodies in a Huichol population of MexicoClinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathyAdvances in autoantibodies in SLEAdvances in the management of septic arthritisOxidized low-density lipoprotein and beta2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis[Idiopathic inflammatory myopathies]Insertion/deletion polymorphism of the angiotensin-converting enzyme gene in lupus nephritis among MexicansAntinuclear antibody test: when to order?Good response to mycophenolate mofetil on treatment of interstitial lung disease in polymyositis associated with antisynthetase syndrome positive for anti-EJ and anti-Ro52 antibodies
P50
Q26782805-39F0BA50-DA4F-4C72-9CEB-21CED50E259EQ34803158-88CE82E1-86D9-4F0C-A4B5-E1EA52D3974EQ36360777-7B7DC3D3-C774-480F-ACCB-63E4114594B7Q36523410-6DFC060B-F211-41AE-A8F6-F81542915A6CQ36791702-93D57B2C-14EE-4D00-828C-A177361E7662Q37444688-E6680254-4EF3-463C-B17E-3155AD968188Q38849144-2ECC818F-94F1-4F94-9697-AC7E98775F28Q38851088-C75540BA-E254-432E-953E-E1AAF6254766Q41928172-D1601CDD-04C4-4D47-B35D-90AB121547C0Q42728719-422E671B-BDA6-4878-83F0-F45BA4FD4388Q44178201-93AB85F6-5D62-49AE-AC1B-D93A12CBA1DFQ46815762-1742E220-AB35-46CE-BD85-E7A07D5390E2Q47653276-D7DA3152-32D9-4A5E-808B-D1051A5271C8Q57245349-9553AC91-8946-459B-A967-33CFA3E83E02Q58051998-D2BF971D-303F-4EE1-82E3-B0E9457809CDQ58052135-8B2FE0CD-6109-4A2D-B77F-3A13A744EC17Q70365330-6C57E3A0-CA37-4F0A-8152-E0BA9B01E296Q71683326-BC243F56-0B04-4023-BF97-F9AEBBAA2F4BQ72345801-31D3136F-4E59-4492-85DF-38CE76F8EECCQ74460392-CA1A6120-7BB8-4801-BE24-934FF1B8C16CQ77719705-75D073F4-C6C6-4DCD-944D-42BC715F3334Q79373818-C937EA52-2847-4801-9591-93045B156837Q82835514-36B7BE57-74A2-4B95-8BF3-645CDA7B796DQ84601151-1626C2F3-A7A1-4876-ADCB-D99DC2E9DAEFQ85394849-90816766-BF81-45AA-B754-355949E0CA05Q85961415-11364A93-B342-406C-ADA9-D59A4EF67B6FQ95843734-1C0CFA2A-AA7A-4578-BB31-CE602A99D871
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ignacio García-De La Torre
@ast
Ignacio García-De La Torre
@en
Ignacio García-De La Torre
@es
Ignacio García-De La Torre
@nl
type
label
Ignacio García-De La Torre
@ast
Ignacio García-De La Torre
@en
Ignacio García-De La Torre
@es
Ignacio García-De La Torre
@nl
prefLabel
Ignacio García-De La Torre
@ast
Ignacio García-De La Torre
@en
Ignacio García-De La Torre
@es
Ignacio García-De La Torre
@nl
P106
P1153
57192032862
7003405032
P21
P31
P496
0000-0002-9261-678X